25 XP   0   0   10

GlycoNex
Buy, Hold or Sell?

Let's analyse Glyconex together

PenkeI guess you are interested in GlycoNex. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GlycoNex. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GlycoNex

I send you an email if I find something interesting about GlycoNex.

Quick analysis of Glyconex (30 sec.)










What can you expect buying and holding a share of Glyconex? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
NT$11.80
Expected worth in 1 year
NT$5.54
How sure are you?
42.9%

+ What do you gain per year?

Total Gains per Share
NT$-6.25
Return On Investment
-25.1%

For what price can you sell your share?

Current Price per Share
NT$24.90
Expected price per share
NT$24.25 - NT$29.60
How sure are you?
50%

1. Valuation of Glyconex (5 min.)




Live pricePrice per Share (EOD)

NT$24.90

Intrinsic Value Per Share

NT$-18.87 - NT$-15.53

Total Value Per Share

NT$-7.07 - NT$-3.73

2. Growth of Glyconex (5 min.)




Is Glyconex growing?

Current yearPrevious yearGrowGrow %
How rich?$39.5m$44.8m-$5.2m-13.3%

How much money is Glyconex making?

Current yearPrevious yearGrowGrow %
Making money-$5.5m-$6.8m$1.2m23.2%
Net Profit Margin-7,016.6%-730.7%--

How much money comes from the company's main activities?

3. Financial Health of Glyconex (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#489 / 1007

Most Revenue
#691 / 1007

Most Profit
#266 / 1007

Most Efficient
#933 / 1007

What can you expect buying and holding a share of Glyconex? (5 min.)

Welcome investor! Glyconex's management wants to use your money to grow the business. In return you get a share of Glyconex.

What can you expect buying and holding a share of Glyconex?

First you should know what it really means to hold a share of Glyconex. And how you can make/lose money.

Speculation

The Price per Share of Glyconex is NT$24.90. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Glyconex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Glyconex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$11.80. Based on the TTM, the Book Value Change Per Share is NT$-1.56 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.80 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Glyconex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps-0.05-0.2%-0.05-0.2%-0.06-0.3%-0.06-0.2%-0.06-0.2%
Usd Book Value Change Per Share-0.05-0.2%-0.05-0.2%0.020.1%-0.01-0.1%0.050.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-0.2%-0.05-0.2%0.020.1%-0.01-0.1%0.050.2%
Usd Price Per Share0.92-0.92-0.94-0.86-0.82-
Price to Earnings Ratio-18.05--18.05--14.99--15.92--14.94-
Price-to-Total Gains Ratio-19.03--19.03-38.01-0.95--0.28-
Price to Book Ratio2.52-2.52-2.28-2.17-1.98-
Price-to-Total Gains Ratio-19.03--19.03-38.01-0.95--0.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.7719
Number of shares1295
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.05-0.01
Usd Total Gains Per Share-0.05-0.01
Gains per Quarter (1295 shares)-62.77-19.00
Gains per Year (1295 shares)-251.09-75.99
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-251-2610-76-86
20-502-5120-152-162
30-753-7630-228-238
40-1004-10140-304-314
50-1255-12650-380-390
60-1507-15160-456-466
70-1758-17670-532-542
80-2009-20180-608-618
90-2260-22690-684-694
100-2511-25200-760-770

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.07.00.00.0%0.07.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.04.00.042.9%3.04.00.042.9%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.07.00.0%0.00.07.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%3.04.00.042.9%3.04.00.042.9%

Fundamentals of Glyconex

About GlycoNex

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.

Fundamental data was last updated by Penke on 2024-04-20 15:08:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of GlycoNex.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Glyconex earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Glyconex to the Biotechnology industry mean.
  • A Net Profit Margin of -7,016.6% means that NT$-70.17 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlycoNex:

  • The MRQ is -7,016.6%. The company is making a huge loss. -2
  • The TTM is -7,016.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-7,016.6%TTM-7,016.6%0.0%
TTM-7,016.6%YOY-730.7%-6,285.9%
TTM-7,016.6%5Y-16,132.4%+9,115.8%
5Y-16,132.4%10Y-19,670.7%+3,538.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7,016.6%-207.2%-6,809.4%
TTM-7,016.6%-214.6%-6,802.0%
YOY-730.7%-281.4%-449.3%
5Y-16,132.4%-428.1%-15,704.3%
10Y-19,670.7%-595.4%-19,075.3%
1.1.2. Return on Assets

Shows how efficient Glyconex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Glyconex to the Biotechnology industry mean.
  • -11.5% Return on Assets means that Glyconex generated NT$-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlycoNex:

  • The MRQ is -11.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.5%TTM-11.5%0.0%
TTM-11.5%YOY-12.8%+1.3%
TTM-11.5%5Y-13.1%+1.6%
5Y-13.1%10Y-13.4%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.5%-12.9%+1.4%
TTM-11.5%-12.3%+0.8%
YOY-12.8%-11.2%-1.6%
5Y-13.1%-13.5%+0.4%
10Y-13.4%-15.1%+1.7%
1.1.3. Return on Equity

Shows how efficient Glyconex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Glyconex to the Biotechnology industry mean.
  • -14.0% Return on Equity means Glyconex generated NT$-0.14 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlycoNex:

  • The MRQ is -14.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.0%TTM-14.0%0.0%
TTM-14.0%YOY-15.2%+1.2%
TTM-14.0%5Y-14.3%+0.3%
5Y-14.3%10Y-14.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.0%-16.5%+2.5%
TTM-14.0%-15.7%+1.7%
YOY-15.2%-14.1%-1.1%
5Y-14.3%-18.8%+4.5%
10Y-14.3%-19.7%+5.4%

1.2. Operating Efficiency of GlycoNex.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Glyconex is operating .

  • Measures how much profit Glyconex makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Glyconex to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlycoNex:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-794.2%+794.2%
TTM-5Y-17,719.4%+17,719.4%
5Y-17,719.4%10Y-21,241.6%+3,522.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--287.3%+287.3%
TTM--226.2%+226.2%
YOY-794.2%-287.8%-506.4%
5Y-17,719.4%-459.1%-17,260.3%
10Y-21,241.6%-598.1%-20,643.5%
1.2.2. Operating Ratio

Measures how efficient Glyconex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 103.84 means that the operating costs are NT$103.84 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of GlycoNex:

  • The MRQ is 103.837. The company is inefficient in keeping operating costs low. -1
  • The TTM is 103.837. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ103.837TTM103.8370.000
TTM103.837YOY9.468+94.369
TTM103.8375Y199.244-95.408
5Y199.24410Y228.598-29.353
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ103.8373.246+100.591
TTM103.8373.303+100.534
YOY9.4683.753+5.715
5Y199.2445.557+193.687
10Y228.5987.396+221.202

1.3. Liquidity of GlycoNex.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Glyconex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.65 means the company has NT$2.65 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of GlycoNex:

  • The MRQ is 2.655. The company is able to pay all its short-term debts. +1
  • The TTM is 2.655. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.655TTM2.6550.000
TTM2.655YOY16.031-13.376
TTM2.6555Y12.009-9.354
5Y12.00910Y16.206-4.198
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6553.821-1.166
TTM2.6554.161-1.506
YOY16.0315.313+10.718
5Y12.0096.113+5.896
10Y16.2066.474+9.732
1.3.2. Quick Ratio

Measures if Glyconex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Glyconex to the Biotechnology industry mean.
  • A Quick Ratio of 2.03 means the company can pay off NT$2.03 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlycoNex:

  • The MRQ is 2.034. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.034. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.034TTM2.0340.000
TTM2.034YOY13.412-11.378
TTM2.0345Y7.766-5.732
5Y7.76610Y7.381+0.385
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0343.474-1.440
TTM2.0343.993-1.959
YOY13.4125.388+8.024
5Y7.7666.105+1.661
10Y7.3816.442+0.939

1.4. Solvency of GlycoNex.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Glyconex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Glyconex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.18 means that Glyconex assets are financed with 17.8% credit (debt) and the remaining percentage (100% - 17.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GlycoNex:

  • The MRQ is 0.178. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.178. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.178TTM0.1780.000
TTM0.178YOY0.158+0.020
TTM0.1785Y0.081+0.097
5Y0.08110Y0.063+0.019
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1780.347-0.169
TTM0.1780.340-0.162
YOY0.1580.272-0.114
5Y0.0810.368-0.287
10Y0.0630.388-0.325
1.4.2. Debt to Equity Ratio

Measures if Glyconex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Glyconex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 21.7% means that company has NT$0.22 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlycoNex:

  • The MRQ is 0.217. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.217. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.217TTM0.2170.000
TTM0.217YOY0.188+0.029
TTM0.2175Y0.095+0.121
5Y0.09510Y0.073+0.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2170.395-0.178
TTM0.2170.411-0.194
YOY0.1880.339-0.151
5Y0.0950.438-0.343
10Y0.0730.469-0.396

2. Market Valuation of GlycoNex

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Glyconex generates.

  • Above 15 is considered overpriced but always compare Glyconex to the Biotechnology industry mean.
  • A PE ratio of -18.05 means the investor is paying NT$-18.05 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlycoNex:

  • The EOD is -15.106. Based on the earnings, the company is expensive. -2
  • The MRQ is -18.049. Based on the earnings, the company is expensive. -2
  • The TTM is -18.049. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.106MRQ-18.049+2.942
MRQ-18.049TTM-18.0490.000
TTM-18.049YOY-14.989-3.060
TTM-18.0495Y-15.919-2.129
5Y-15.91910Y-14.940-0.979
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.106-2.437-12.669
MRQ-18.049-2.599-15.450
TTM-18.049-2.764-15.285
YOY-14.989-4.018-10.971
5Y-15.919-6.401-9.518
10Y-14.940-6.590-8.350
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GlycoNex:

  • The EOD is -12.995. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.526. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.526. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.995MRQ-15.526+2.531
MRQ-15.526TTM-15.5260.000
TTM-15.526YOY-18.696+3.170
TTM-15.5265Y-17.822+2.296
5Y-17.82210Y-16.509-1.313
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.995-3.111-9.884
MRQ-15.526-3.321-12.205
TTM-15.526-3.598-11.928
YOY-18.696-5.480-13.216
5Y-17.822-8.353-9.469
10Y-16.509-8.955-7.554
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Glyconex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.52 means the investor is paying NT$2.52 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of GlycoNex:

  • The EOD is 2.111. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.522. Based on the equity, the company is underpriced. +1
  • The TTM is 2.522. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.111MRQ2.522-0.411
MRQ2.522TTM2.5220.000
TTM2.522YOY2.279+0.243
TTM2.5225Y2.174+0.348
5Y2.17410Y1.977+0.196
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.1112.051+0.060
MRQ2.5222.143+0.379
TTM2.5222.120+0.402
YOY2.2792.878-0.599
5Y2.1743.601-1.427
10Y1.9773.972-1.995
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GlycoNex compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.564-1.5640%0.801-295%-0.473-70%1.685-193%
Book Value Per Share--11.79611.7960%13.360-12%12.793-8%13.592-13%
Current Ratio--2.6552.6550%16.031-83%12.009-78%16.206-84%
Debt To Asset Ratio--0.1780.1780%0.158+13%0.081+118%0.063+183%
Debt To Equity Ratio--0.2170.2170%0.188+15%0.095+127%0.073+197%
Dividend Per Share----0%-0%-0%-0%
Eps---1.648-1.6480%-2.031+23%-1.813+10%-1.904+16%
Free Cash Flow Per Share---1.916-1.9160%-1.629-15%-1.589-17%-1.632-15%
Free Cash Flow To Equity Per Share---1.916-1.9160%3.216-160%0.107-1893%-0.415-78%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---15.527--------
Intrinsic Value_10Y_min---18.868--------
Intrinsic Value_1Y_max---1.586--------
Intrinsic Value_1Y_min---1.719--------
Intrinsic Value_3Y_max---4.741--------
Intrinsic Value_3Y_min---5.343--------
Intrinsic Value_5Y_max---7.870--------
Intrinsic Value_5Y_min---9.137--------
Market Cap2694379200.000-19%3219188000.0003219188000.0000%3294933600.000-2%3004936160.000+7%2856601541.943+13%
Net Profit Margin---70.166-70.1660%-7.307-90%-161.324+130%-196.707+180%
Operating Margin----0%-7.9420%-177.1940%-212.4160%
Operating Ratio--103.837103.8370%9.468+997%199.244-48%228.598-55%
Pb Ratio2.111-19%2.5222.5220%2.279+11%2.174+16%1.977+28%
Pe Ratio-15.106+16%-18.049-18.0490%-14.989-17%-15.919-12%-14.940-17%
Price Per Share24.900-19%29.75029.7500%30.450-2%27.770+7%26.399+13%
Price To Free Cash Flow Ratio-12.995+16%-15.526-15.5260%-18.696+20%-17.822+15%-16.509+6%
Price To Total Gains Ratio-15.925+16%-19.026-19.0260%38.013-150%0.951-2100%-0.285-99%
Quick Ratio--2.0342.0340%13.412-85%7.766-74%7.381-72%
Return On Assets---0.115-0.1150%-0.128+11%-0.131+14%-0.134+16%
Return On Equity---0.140-0.1400%-0.152+9%-0.143+2%-0.143+2%
Total Gains Per Share---1.564-1.5640%0.801-295%-0.473-70%1.685-193%
Usd Book Value--39568865.00039568865.0000%44813941.000-12%42912624.200-8%45592541.429-13%
Usd Book Value Change Per Share---0.048-0.0480%0.025-295%-0.015-70%0.052-193%
Usd Book Value Per Share--0.3660.3660%0.414-12%0.397-8%0.421-13%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.051-0.0510%-0.063+23%-0.056+10%-0.059+16%
Usd Free Cash Flow---6427602.000-6427602.0000%-5463347.000-15%-5330753.800-17%-5473461.857-15%
Usd Free Cash Flow Per Share---0.059-0.0590%-0.050-15%-0.049-17%-0.051-15%
Usd Free Cash Flow To Equity Per Share---0.059-0.0590%0.100-160%0.003-1893%-0.013-78%
Usd Market Cap83525755.200-19%99794828.00099794828.0000%102142941.600-2%93153020.960+7%88554647.800+13%
Usd Price Per Share0.772-19%0.9220.9220%0.944-2%0.861+7%0.818+13%
Usd Profit---5529222.000-5529222.0000%-6814482.000+23%-6079937.000+10%-6386735.143+16%
Usd Revenue--78802.00078802.0000%932635.000-92%243579.400-68%180893.857-56%
Usd Total Gains Per Share---0.048-0.0480%0.025-295%-0.015-70%0.052-193%
 EOD+3 -5MRQTTM+0 -0YOY+7 -255Y+11 -2110Y+11 -21

3.2. Fundamental Score

Let's check the fundamental score of GlycoNex based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-15.106
Price to Book Ratio (EOD)Between0-12.111
Net Profit Margin (MRQ)Greater than0-70.166
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.034
Current Ratio (MRQ)Greater than12.655
Debt to Asset Ratio (MRQ)Less than10.178
Debt to Equity Ratio (MRQ)Less than10.217
Return on Equity (MRQ)Greater than0.15-0.140
Return on Assets (MRQ)Greater than0.05-0.115
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of GlycoNex based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose25.450
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets1,552,814
Total Liabilities276,399
Total Stockholder Equity1,276,415
 As reported
Total Liabilities 276,399
Total Stockholder Equity+ 1,276,415
Total Assets = 1,552,814

Assets

Total Assets1,552,814
Total Current Assets718,333
Long-term Assets834,481
Total Current Assets
Cash And Cash Equivalents 149,467
Short-term Investments 550,308
Net Receivables 25
Other Current Assets 1,130
Total Current Assets  (as reported)718,333
Total Current Assets  (calculated)700,930
+/- 17,403
Long-term Assets
Property Plant Equipment 813,650
Long-term Assets Other 8,218
Long-term Assets  (as reported)834,481
Long-term Assets  (calculated)821,868
+/- 12,613

Liabilities & Shareholders' Equity

Total Current Liabilities270,583
Long-term Liabilities5,816
Total Stockholder Equity1,276,415
Total Current Liabilities
Short Long Term Debt 900
Other Current Liabilities 214,230
Total Current Liabilities  (as reported)270,583
Total Current Liabilities  (calculated)215,130
+/- 55,453
Long-term Liabilities
Long-term Liabilities Other 5,816
Long-term Liabilities  (as reported)5,816
Long-term Liabilities  (calculated)5,816
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)1,276,415
Total Stockholder Equity (calculated)0
+/- 1,276,415
Other
Capital Stock1,086,401
Common Stock Shares Outstanding 108,208
Net Invested Capital 1,277,315
Net Working Capital 447,750
Property Plant and Equipment Gross 813,650



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
> Total Assets 
1,866,435
1,561,801
1,332,214
1,574,044
1,395,003
1,716,948
1,552,814
1,552,8141,716,9481,395,0031,574,0441,332,2141,561,8011,866,435
   > Total Current Assets 
595,718
360,811
186,405
499,160
358,688
713,127
718,333
718,333713,127358,688499,160186,405360,811595,718
       Cash And Cash Equivalents 
442,921
256,169
118,742
152,740
125,067
82,187
149,467
149,46782,187125,067152,740118,742256,169442,921
       Short-term Investments 
138,056
91,320
61,700
326,216
206,526
596,582
550,308
550,308596,582206,526326,21661,70091,320138,056
       Net Receivables 
880
451
3,429
16
350
46
25
2546350163,429451880
       Other Current Assets 
1,233
349
20
155
140
310
1,130
1,130310140155203491,233
   > Long-term Assets 
1,270,717
1,200,990
1,145,809
1,074,884
1,036,315
1,003,821
834,481
834,4811,003,8211,036,3151,074,8841,145,8091,200,9901,270,717
       Property Plant Equipment 
1,170,808
1,131,509
1,090,989
1,054,652
1,021,936
989,919
813,650
813,650989,9191,021,9361,054,6521,090,9891,131,5091,170,808
       Other Assets 
40,664
39,069
36,490
249
174
384
0
038417424936,49039,06940,664
> Total Liabilities 
25,187
29,350
31,359
34,467
36,070
271,337
276,399
276,399271,33736,07034,46731,35929,35025,187
   > Total Current Liabilities 
16,932
19,805
21,539
25,573
27,206
44,484
270,583
270,58344,48427,20625,57321,53919,80516,932
       Short Long Term Debt 
2,128
2,725
2,203
900
900
5,900
900
9005,9009009002,2032,7252,128
       Accounts payable 
2,128
2,725
2,203
900
900
900
0
09009009002,2032,7252,128
       Other Current Liabilities 
3,466
2,979
2,942
5,643
5,852
5,744
214,230
214,2305,7445,8525,6432,9422,9793,466
   > Long-term Liabilities 
8,255
9,545
9,820
8,894
8,864
226,853
5,816
5,816226,8538,8648,8949,8209,5458,255
       Other Liabilities 
8,255
9,545
9,820
8,894
8,864
8,174
0
08,1748,8648,8949,8209,5458,255
> Total Stockholder Equity
1,841,248
1,532,451
1,300,855
1,539,577
1,358,933
1,445,611
1,276,415
1,276,4151,445,6111,358,9331,539,5771,300,8551,532,4511,841,248
   Common Stock
764,985
765,035
761,610
975,078
974,818
1,070,980
0
01,070,980974,818975,078761,610765,035764,985
   Retained Earnings Total Equity0000000
   Accumulated Other Comprehensive Income 0000000
   Capital Surplus 0000000
   Treasury Stock0000000
   Other Stockholders Equity 
-18,736
-11,350
8,569
422
-6,874
5,858
0
05,858-6,8744228,569-11,350-18,736



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,542
Cost of Revenue-1,547
Gross Profit995995
 
Operating Income (+$)
Gross Profit995
Operating Expense-262,406
Operating Income-259,864-261,411
 
Operating Expense (+$)
Research Development210,381
Selling General Administrative50,478
Selling And Marketing Expenses0
Operating Expense262,406260,859
 
Net Interest Income (+$)
Interest Income9,366
Interest Expense-5,712
Other Finance Cost-0
Net Interest Income3,654
 
Pretax Income (+$)
Operating Income-259,864
Net Interest Income3,654
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-163,717-259,864
EBIT - interestExpense = -5,712
-178,362
-172,650
Interest Expense5,712
Earnings Before Interest and Taxes (EBIT)0-158,005
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-163,717
Tax Provision-14,645
Net Income From Continuing Ops-178,362-178,362
Net Income-178,362
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-3,654
 

Technical Analysis of Glyconex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Glyconex. The general trend of Glyconex is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Glyconex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GlycoNex.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 28.65 < 29.60 < 29.60.

The bearish price targets are: 25.00 > 24.50 > 24.25.

Tweet this
GlycoNex Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GlycoNex. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GlycoNex Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GlycoNex.

GlycoNex Daily Moving Average Convergence/Divergence (MACD) ChartGlycoNex Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GlycoNex. The current adx is .

GlycoNex Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GlycoNex.

GlycoNex Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GlycoNex.

GlycoNex Daily Relative Strength Index (RSI) ChartGlycoNex Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GlycoNex.

GlycoNex Daily Stochastic Oscillator ChartGlycoNex Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GlycoNex.

GlycoNex Daily Commodity Channel Index (CCI) ChartGlycoNex Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GlycoNex.

GlycoNex Daily Chande Momentum Oscillator (CMO) ChartGlycoNex Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GlycoNex.

GlycoNex Daily Williams %R ChartGlycoNex Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GlycoNex.

GlycoNex Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GlycoNex.

GlycoNex Daily Average True Range (ATR) ChartGlycoNex Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GlycoNex.

GlycoNex Daily On-Balance Volume (OBV) ChartGlycoNex Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GlycoNex.

GlycoNex Daily Money Flow Index (MFI) ChartGlycoNex Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GlycoNex.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

GlycoNex Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GlycoNex based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose25.450
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Glyconex with someone you think should read this too:
  • Are you bullish or bearish on Glyconex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Glyconex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GlycoNex

I send you an email if I find something interesting about GlycoNex.


Comments

How you think about this?

Leave a comment

Stay informed about GlycoNex.

Receive notifications about GlycoNex in your mailbox!